Overview of Vaccine Preventable Disease (VPD) Surveillance in the United States
Post on 24-Feb-2016
55 Views
Preview:
DESCRIPTION
Transcript
Sandra W. Roush, MT, MPHSurveillance Officer, CDC/NCIRD
August 7, 2012NCHS 2012 National Conference on Health Statistics
Overview of Vaccine Preventable Disease (VPD) Surveillance in the United States
National Center for Immunization and Respiratory DiseasesOverview of Vaccine Preventable Disease (VPD) Surveillance in the US
Presentation Objectives
Discuss:
• Purpose of vaccine-preventable disease (VPD) surveillance
• Types of surveillance data collected• Surveillance systems/methods• Support for VPD surveillance
Purpose of vaccine-preventable disease (VPD) surveillance
Purpose of Vaccine-Preventable Disease Surveillance
• Estimate burden of disease• Evaluate control measures• Determine geographic distribution• Portray the natural history• Detect epidemics/define a problem• Generate hypotheses, stimulate research• Monitor changes in infectious agents• Detect changes in health practices• Facilitate planning
Comparison of 20th Century Annual Morbidity and Current Morbidity: Vaccine-Preventable Diseases
Disease20th Century
Annual Morbidity†2011
Reported Cases † †Percent Decrease
Smallpox 29,005 0 100%
Diphtheria 21,053 0 100%
Measles 530,217 212 > 99%
Mumps 162,344 370 > 99%
Pertussis 200,752 15,216 92%
Polio (paralytic) 16,316 0 100%
Rubella 47,745 4 > 99%
Congenital Rubella Syndrome 152 0 100%
Tetanus 580 9 98%
Haemophilus influenzae 20,000 8* > 99%†Source: JAMA. 2007;298(18):2155-2163† † Source: CDC. MMWR January 6, 2012;60(51);1762-1775. (provisional 2011 data) * Haemophilus influenzae type b (Hib) < 5 years of age. An additional 14 cases of Hib are estimated to have occurred among the 237 reports of Hi (< 5 years of age) with unknown serotype.
Comparison of Pre-Vaccine Era Estimated Annual Morbidity with Current Estimate: Vaccine-Preventable
Diseases
Disease Pre-Vaccine Era Annual Estimate
2010 Estimate Percent Decrease
Hepatitis A 117,333 † 7,138 94%Hepatitis B (acute) 66,232 † 9,428 86%Pneumococcus (invasive)
all ages 63,067 † 39,500 # 37%
< 5 years of age 16,069 † 4,400## 73%
Rotavirus (hospitalizations, < 3 years of age)
Varicella
62,500 † †
4,085,120 †
2,500###
281,873
96%
93%
† Source: JAMA. 2007;298(18):2155-2163†† Source: CDC. MMWR. February 6, 2009 / 58(RR02);1-25# Source: CDC. Active Bacterial Core surveillance Provisional Report; S. pneumoniae 2010. http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.htmll## Source: 2010 (provisional) Active Bacterial Core surveillance ### Source: New Vaccine Surveillance Network (unpublished)
Types of VPD surveillance data collected
1922
1930
1940
1950
1960
1970
1980
1990
2000
2010
0
50,000
100,000
150,000
200,000
250,000
300,000
Year
Num
ber o
f cas
esReported Pertussis Cases, 1922–2010
DTP
1990
1995
2000
2005
2010
0
5,000
10,000
15,000
20,000
25,000
30,000
Tdap
DTaP
SOURCE: CDC, National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System and 1922-1949, passive reports to the Public Health Service
Reported Pertussis Cases by Diagnosis± 1990-2010
1990 1995 2000 2005 20100
5000
10000
15000
20000
25000
30000
UnknownSero+(MA)Epi-linkedDFAPCRCulture
Year
Num
ber o
f Cas
es
±Data collection for PCR and Epi-Link began in 1995Source: CDC, National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System, 2010
Measles Cases, United States, 1962-2011
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
0
100,000
200,000
300,000
400,000
500,000
600,000
Year
Num
ber o
f cas
es
1989 – 2nd Dose Recommended
0
5,000
10,000
15,000
20,000
25,000
30,000
1963Vaccine
Licensed1989-1991
Resurgence
1993Vaccines for
Children Program
2000 Elimination
Declared
Measles, United States, 2001-2011Importations by WHO Region
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 20110
10
20
30
40
50
60
70
80 UnknownWestern Pacific(WPR)South East Asian(SEAR)European(EUR)Eastern Mediterranean(EMR)African(AFR)American(AMR)
Year
Num
ber o
f Cas
es
Critical Elements in National Surveillance for VPDs
• Demographic data• Clinical history• Vaccination history• Laboratory testing, confirmation,
and molecular epidemiology • Role of importation
Surveillance systems/methods
VPD Surveillance Data Sources in the U.S.• State-based national passive surveillance
(National Notifiable Disease Surveillance System - NNDSS)
• Sentinel sites with active surveillance• Administrative data reviews (hospital
discharge data and other resources)• Special studies for specific diseases or
conditions• Laboratory-based studies
NNDSS: Case Reporting and Case Notification in the U.S.
Local Health Department
State Health Department
Laboratoryreporting
Health Care Provider reporting
CDC• 50 states• 64 grantees• > 3,000
counties
notification
States’ Participation in National VPD Surveillance
• List of nationally notifiable diseases from the Council of State and Territorial Epidemiologists (CSTE), with individual state implementation
• Case definitions determined by CSTE, to improve specificity and enhance comparability of cases (suspect, probable, confirmed)
• Laboratory support from Association of Public Health Laboratories (APHL)
National VPD Surveillance Data in the U.S.
• Reporting completeness varies (10%-90%)• Limited federal funding is available specifically
for surveillance • Number of case reports changes related to
disease incidence, but also due to testing technology, state laws, provider awareness
Support for vaccine-preventable disease (VPD) surveillance
Federal Assistance for VPD Surveillance
• Immunization program grant/cooperative agreement and special projects
• Technical assistance– Consultation and epidemiologic response– Standards of practice: Manual for the
Surveillance of Vaccine-Preventable Diseases http://www.cdc.gov/vaccines/pubs/surv-manual/ and Immunization Program Operations Manual
• Laboratory support
Federal Assistance for VPD Surveillance, continued
• Information dissemination – Weekly/annual MMWR surveillance
summaries– Manuscripts and other venues
• Electronic data transmission, including demographic and epidemiologic case information (NETSS, NEDSS)
• Monitoring national surveillance indicators (imported cases, laboratory confirmation, timeliness, completeness, and others)
top related